Pricing Log in Create free account
Friday 6 November 2026 Export SMMT’s income statement to Excel — free account

Summit Therapeutics PLC

SMMT Healthcare Biotechnology

Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.

EPS
+63.2%
Free cash flow
−112.8%

Quarter to June 2026, against a year earlier

15.85 1.66 +11.70%
Market cap
$11.3B
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
0.88
Beneish M
−5.00
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Summit Therapeutics PLC (SMMT) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Nov 4, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Sep 30, 2026 P1I2: 24 added · 4 removed · 62 modified
P2I1A: no material changes, the filing says 		Short cash runway Share dilution
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
8-K Sep 28, 2026 1.01 Entry into a material definitive agreement; 3.02 Unregistered sales of equity securities; 5.03 Amendments to the articles or bylaws; change in fiscal year; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 15, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 13, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 2, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 25, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 5, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jul 23, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 9 added · 3 removed · 29 modified
P2I1A: no changes
8-K Jul 23, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jul 22, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jun 10, 2026 5.07 Submission of matters to a vote of security holders
8-K Jun 10, 2026 7.01 Regulation FD disclosure
8-K Jun 2, 2026 8.01 Other events
8-K May 30, 2026 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 50 added · 18 removed · 125 modified
1A: 24 added · 18 removed · 83 modified
7: 17 added · 19 removed · 34 modified
8-K Feb 23, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 29, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 7, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Oct 21, 2025 1.01 Entry into a material definitive agreement; 3.02 Unregistered sales of equity securities; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 17, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Sep 7, 2025 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 11, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-Q Mar 31, 2025
8-K May 1, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 24, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 13, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 30, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 6, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 1, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 20, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 8, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 7, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.